Related Experiment Videos
Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis
James E Korkola1, Sandy DeVries, Jane Fridlyand
1Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143-0808, USA.
Cancer Research
|November 13, 2003
Summary
Gene expression differences distinguish invasive lobular and ductal breast tumors. This study identified key genes, like E-cadherin, that may explain the distinct biology of these breast cancer subtypes.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) exhibit distinct clinical and histological features.
- The molecular underpinnings differentiating ILC and IDC, beyond E-cadherin, remain largely unexplored.
Purpose of the Study:
- To identify genes with differential expression between ILC and IDC using cDNA microarrays.
- To elucidate the molecular basis for the phenotypic distinctions between these two major breast cancer subtypes.
Main Methods:
- Utilized cDNA microarrays to analyze gene expression profiles of lobular and ductal breast tumors.
- Employed Prediction Analysis for Microarrays (PAM), MaxT permutation analysis, and Significance Analysis for Microarrays (SAM) to identify differentially expressed genes.
- Validated differential gene expression using real-time quantitative PCR.
Main Results:
- Prediction Analysis for Microarrays (PAM) accurately classified tumor types with 93.7% accuracy.
- Identified multiple genes significantly differentially expressed between ILC and IDC, including E-cadherin, survivin, cathepsin B, and osteopontin.
- Real-time quantitative PCR confirmed differential expression for seven key genes.
Conclusions:
- Specific gene expression profiles distinguish lobular from ductal breast carcinomas.
- The identified genes offer insights into the distinct biological behaviors and phenotypic differences of ILC and IDC.
- These findings may contribute to a better understanding and potential therapeutic strategies for breast cancer subtypes.